Michele Gaiotto

Michele Gaiotto has extensive experience in various roles within the healthcare and investment industry. Currently, they are the Managing Principal at HTH since January 2020. Prior to this, they worked as the Investment Lead - ZCUBE Research Venture at Zambon starting from January 2017. In addition, they hold the position of a Non-Executive Board Member at Leuko since August 2022. Furthermore, Michele has served as a Member of the Board of Directors at Endostart s.r.l. from April 2021, where they contributed to making colonoscopy procedures safer and more efficient. Michele also worked as a Board Observer at Delpor, Inc. since August 2018, focusing on developing long-lasting therapies for chronic diseases. Michele Gaiotto has continued their involvement in the medical field by serving as a Board Observer at Neurofenix since December 2023. Additionally, they hold the position of Member of the Board of Directors at MDConcierge starting from April 2021, aiming to provide personalized medical assistance. Michele has also worked as the Alternative Investments Head at Secofind SIM SpA commencing in April 2021. Previously, they worked as the Managing Director and Member of the Board of Directors at MyAir Inc from July 2020 until March 2023. Lastly, Michele served as a Member of the Board of Directors at SOM Biotech from December 2018 to February 2021.

Michele Gaiotto holds a Bachelor's degree in Statistics with a focus on IT & Biostatistics, Multivariate Statistics, and Neural Networks from Università degli Studi di Padova, which they earned from 2008 to 2011. Michele then pursued a Master's degree in Statistics from the same university, completing the program from 2011 to 2013. In 2013, they obtained their Charterholder designation from the CFA Institute, specializing in Investments and Securities. Additionally, they obtained a Chartered Alternative Investments Analyst certification from the CAIA Association in 2015-2016.